Format

Send to

Choose Destination
Clin Res Hepatol Gastroenterol. 2017 Sep;41(4):357-369. doi: 10.1016/j.clinre.2016.11.002. Epub 2016 Dec 15.

CD40 signaling and hepatic steatosis: Unanticipated links.

Author information

1
INSERM U1026, Université de Bordeaux, 33000 Bordeaux, France.
2
Cell and Developmental Biology Programme, Centre for Genomic Regulation, 08003 Barcelona, Spain.
3
Service d'Anesthésie-Réanimation II, CHU de Bordeaux, 33600 Pessac, France.
4
Service de Biochimie, CHU de Bordeaux, 33000 Bordeaux, France.
5
EA 6309, Université de Limoges, 87000 Limoges, France.
6
INSERM U1026, Université de Bordeaux, 33000 Bordeaux, France. Electronic address: jean.ripoche@u-bordeaux.fr.

Abstract

Obesity predisposes to an increased risk of nonalcoholic fatty liver disease (NAFLD). Hepatic steatosis is the key pathological feature of NAFLD and has emerged as a metabolic disorder in which innate and adaptive arms of the immune response play a central role in disease pathogenesis. Recent studies have revealed unexpected relationships between CD40 signaling and hepatic steatosis in high fat diet rodent models. CD154, the ligand of CD40, is a mediator of inflammation and controls several critical events of innate and adaptive immune responses. In the light of these reports, we discuss potential links between CD40 signaling and hepatic steatosis in NAFLD.

PMID:
27989689
DOI:
10.1016/j.clinre.2016.11.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center